Assessing the feasibility of conducting and using health technology assessment in Colombia: The case of severe haemophilia A

Health Technology Assessment (HTA) examines the consequences of the application of health technologies. HTA is aimed at better informing decision-makers. In November 2012 Colombia established its own HTA agency (IETS). Up until the establishment of IETS, HTA had had a limited role in providing information to set priorities. Severe haemophilia A (SHA), an infrequent disorder of blood coagulation, serves as a good example of how the adoption of new technologies can change the course of a disease while challenging the financial sustainability of health systems. The aim of this study was to assess the feasibility of conducting and using HTA to inform decisionmaking in Colombia. To fulfil these aims a mixed methods approach was used. Because decisionmaking is a task embedded in a complex and highly customised context, the case study method was considered as appropriate. Through a qualitative approach using semi- structured interviews ten “drivers” emerged with the ability to help or hinder HTA: availability and quality of data, implementation strategy, cultural aspects, local capacity, financial support, policy/political support, globalisation, stakeholder pressure, health system context and usefulness perception. A CUA from the Colombian health system perspective was developed to assess the cost-effectiveness of primary prophylaxis (PP) versus on-demand (OD) provision of FVIII for SHA. The ICER of PP with FVIII compared to OD was COL$105,081,022 (USD$55,204) per QALY gained. This is not considered costeffective using a hypothetical threshold of up to three times the GDP per-capita.Two approaches were used to assist decision-making for PP in Colombia, including EVIDEM. The final reimbursement decision about PP in Colombia would be “it would not be prioritised”. Nonetheless, the final valuation of technologies was sensitive to the methods and criteria used to assist decisionmaking. The combined results of the research appear to suggest that HTA development and use in Colombia is feasible, even for technologies that are difficult to evaluate. Results of this research work could be of significant value to the field of public health and policy since resource-allocation decisions in many settings similar to Colombia have often been made without enough evidence-based information. Further research in the field of priority-setting is still required.

[1]  A. Briggs,et al.  Something old, something new, something borrowed, something blue: a framework for the marriage of health econometrics and cost-effectiveness analysis. , 2002, Health economics.

[2]  D. Eddy Clinical decision making: from theory to practice. Anatomy of a decision. , 1990, JAMA.

[3]  H. M. van den Berg,et al.  A survey of adherence to haemophilia therapy in six European countries: results and recommendations , 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

[4]  P. Babyn,et al.  Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study , 2006, Journal of thrombosis and haemostasis : JTH.

[5]  Carol Grbich,et al.  Qualitative Research in Health: An Introduction , 1999 .

[6]  Pierre Pluye,et al.  Understanding divergence of quantitative and qualitative data (or results) in mixed methods studies , 2009 .

[7]  N. Britten Qualitative Research: Qualitative interviews in medical research , 1995 .

[8]  R. Ljung,et al.  Factor VIII products and inhibitor development in severe hemophilia A. , 2013, The New England journal of medicine.

[9]  A. Iorio,et al.  Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B. , 2006, The Cochrane database of systematic reviews.

[10]  A. Farrugia,et al.  Health technology assessment and haemophilia , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

[11]  L. Mantovani,et al.  A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study) , 2011, Journal of thrombosis and haemostasis : JTH.

[12]  R. Carter,et al.  Health technology assessment: reflections from the Antipodes. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[13]  M. Goetghebeur,et al.  Field testing of a multicriteria decision analysis (MCDA) framework for coverage of a screening test for cervical cancer in South Africa , 2012, Cost Effectiveness and Resource Allocation.

[14]  K. Fischer,et al.  Treatment for life for severe haemophilia A– A cost‐utility model for prophylaxis vs. on‐demand treatment , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[15]  S. Simoens Use of Economic Evaluation in Decision Making , 2010, Drugs.

[16]  A S Detsky,et al.  How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. , 1992, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

[17]  G. Batty,et al.  The advantages of being called NICE: a systematic review of journal article titles using the acronym for the National Institute for Health and Clinical Excellence. , 2008, Journal of public health.

[18]  C. Pashos,et al.  Health technology assessment: lessons learned from around the world--an overview. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[19]  C. Deal,et al.  Combining multicriteria decision analysis, ethics and health technology assessment: applying the EVIDEM decisionmaking framework to growth hormone for Turner syndrome patients , 2010, Cost effectiveness and resource allocation : C/E.

[20]  R. Tedder,et al.  Hepatitis C viral RNA in clotting factor concentrates and the development of hepatitis in recipients. , 1993, Blood.

[21]  B. Evatt,et al.  The tragic history of AIDS in the hemophilia population, 1982–1984 , 2006, Journal of thrombosis and haemostasis : JTH.

[22]  K. Charmaz,et al.  Constructing Grounded Theory: A practical guide through qualitative analysis Kathy Charmaz Constructing Grounded Theory: A practical guide through qualitative analysis Sage 224 £19.99 0761973532 0761973532 [Formula: see text]. , 2006, Nurse researcher.

[23]  Lydia Kapiriri,et al.  Setting priorities for health interventions in developing countries: a review of empirical studies , 2009, Tropical medicine & international health : TM & IH.

[24]  Murray D. Krahn,et al.  INTRODUCTION TO HEALTH TECHNOLOGY ASSESSMENT , 2014 .

[25]  S. Homan,et al.  Determining Transition Probabilities , 1994, Medical decision making : an international journal of the Society for Medical Decision Making.

[26]  Karl Claxton,et al.  Assessing Quality in Decision Analytic Cost-Effectiveness Models , 2000, PharmacoEconomics.

[27]  K. Fischer,et al.  Comparing outcomes of different treatment regimens for severe haemophilia , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

[28]  S. Oliver,et al.  Involving consumers in a needs‐led research programme: a pilot project , 2001, Health expectations : an international journal of public participation in health care and health policy.

[29]  A Laupacis,et al.  The effect of elective total hip replacement on health-related quality of life. , 1993, The Journal of bone and joint surgery. American volume.

[30]  P. Mannucci,et al.  AIDS, hepatitis and hemophilia in the 1980s: memoirs from an insider , 2003, Journal of thrombosis and haemostasis : JTH.

[31]  Edward G. D. Tuddenham,et al.  Erratum: The hemophilias - From royal genes to gene therapy (New England Journal of Medicine (June 7, 2001) 344 (1773-9)) , 2001 .

[32]  Montse Moharra,et al.  Addressing issues in health technology assessment promotion: Motives, enablers, and barriers , 2011, International Journal of Technology Assessment in Health Care.

[33]  P. Shekelle,et al.  Validity of the Agency for Healthcare Research and Quality clinical practice guidelines: how quickly do guidelines become outdated? , 2001, JAMA.

[34]  K. Kurnik,et al.  Identification and long‐term observation of early joint damage by magnetic resonance imaging in clinically asymptomatic joints in patients with haemophilia A or B despite prophylaxis , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

[35]  Jon Sussex,et al.  Critique of CHE Research Paper 81: Methods for the Estimation of the NICE Cost Effectiveness Threshold , 2013 .

[36]  Donald G. Saari,et al.  Mathematical Structure of Voting Paradoxes: II. Positional Voting , 1999 .

[37]  J Hjelmgren,et al.  Health economic guidelines--similarities, differences and some implications. , 2001, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[38]  K. Amfo Health technology assessment. , 1996, World health forum.

[39]  L. Garrison,et al.  Using real-world data for coverage and payment decisions: the ISPOR Real-World Data Task Force report. , 2007, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[40]  A. Diederich,et al.  Age as a Criterion for Setting Priorities in Health Care? A Survey of the German Public View , 2011, PloS one.

[41]  J. Kirk,et al.  Reliability and Validity in Qualitative Research , 1985 .

[42]  G. Auerswald,et al.  New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development , 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

[43]  J. Aznar,et al.  Results of an orthopaedic survey in young patients with severe haemophilia in Spain , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

[44]  K. Fischer,et al.  Changes in treatment strategies for severe haemophilia over the last 3 decades: effects on clotting factor consumption and arthropathy , 2001, Haemophilia : the official journal of the World Federation of Hemophilia.

[45]  A Gafni,et al.  Cost effectiveness/utility analyses. Do current decision rules lead us to where we want to be? , 1992, Journal of health economics.

[46]  Anselm L. Strauss,et al.  Awareness of Dying , 1966 .

[47]  P. Giangrande Blood Products for Hemophilia , 2012, BioDrugs.

[48]  Paul Kind,et al.  From efficacy to equity: Literature review of decision criteria for resource allocation and healthcare decisionmaking , 2012, Cost Effectiveness and Resource Allocation.

[49]  David Hailey,et al.  TOWARD TRANSPARENCY IN HEALTH TECHNOLOGY ASSESSMENT , 2003, International Journal of Technology Assessment in Health Care.

[50]  A. Gafni,et al.  Changing the problem to fit the solution: Johannesson and Weinstein's (mis) application of economics to real world problems. , 1993, Journal of health economics.

[51]  M. Ezzati,et al.  [Priority setting for health interventions in Mexico's System of Social Protection in Health]. , 2007, Salud publica de Mexico.

[52]  Ingrid M. Nembhard,et al.  Qualitative and Mixed Methods Provide Unique Contributions to Outcomes Research , 2009, Circulation.

[53]  J. Gill,et al.  Home Treatment of Mild to Moderate Bleeding Episodes Using Recombinant Factor VIIa (Novoseven) in Haemophiliacs with Inhibitors , 1998, Thrombosis and Haemostasis.

[54]  K. Chalkidou,et al.  Priority-setting institutions in health: recommendations from a center for global development working group. , 2012, Global heart.

[55]  C. Mitton,et al.  Cost effectiveness analysis in health care: contraindications , 2002, BMJ : British Medical Journal.

[56]  Aris Angelis,et al.  Multiple criteria decision analysis for valuebased assessment of new medical technologies:a conceptual framework , 2013 .

[57]  H. A. Lingstone,et al.  The Delphi Method: Techniques and Applications , 1976 .

[58]  Graham Loomes,et al.  Valuing Life Years and QALYs: Transferability and Convertability of Values Across the UK Public Sector , 2002 .

[59]  Derek J. Pike,et al.  Empirical Model‐building and Response Surfaces. , 1988 .

[60]  C. Lindblom THE SCIENCE OF MUDDLING THROUGH , 1959 .

[61]  Staffan Larsson Life expectancy of Swedish haemophiliacs, 1831–1980 , 1985, British journal of haematology.

[62]  R. Ljung,et al.  Devising a best practice approach to prophylaxis in boys with severe haemophilia: evaluation of current treatment strategies , 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

[63]  Michael E. Chernew,et al.  Willingness to Pay for a Quality-adjusted Life Year , 2000, Medical decision making : an international journal of the Society for Medical Decision Making.

[64]  A. Strauss,et al.  The discovery of grounded theory: strategies for qualitative research aldine de gruyter , 1968 .

[65]  Paul Kind,et al.  WHICH CRITERIA ARE CONSIDERED IN HEALTHCARE DECISIONS? INSIGHTS FROM AN INTERNATIONAL SURVEY OF POLICY AND CLINICAL DECISION MAKERS , 2013, International Journal of Technology Assessment in Health Care.

[66]  Grazyna Adamiak,et al.  Methods for the economic evaluation of health care programmes, 3rd ed , 2006 .

[67]  Mandy Ryan,et al.  Using discrete choice experiments to value health and health care , 2008 .

[68]  J. Lusher,et al.  Factor VIII inhibitors with recombinant products : prospective clinical trials. Discussion , 2000 .

[69]  S. Wilson Methods for the economic evaluation of health care programmes , 1987 .

[70]  J Chilcott,et al.  Avoiding and identifying errors in health technology assessment models: qualitative study and methodological review. , 2010, Health technology assessment.

[71]  R. Ljung The risk associated with indwelling catheters in children with haemophilia , 2007, British journal of haematology.

[72]  Giuseppe Barletta,et al.  Introduction to health technology assessment , 2012 .

[73]  C. Pope,et al.  Assessing quality in qualitative research , 2000, BMJ : British Medical Journal.

[74]  D. Grobbee,et al.  Prophylactic versus on‐demand treatment strategies for severe haemophilia: a comparison of costs and long‐term outcome , 2002, Haemophilia : the official journal of the World Federation of Hemophilia.

[75]  Ricardo Sánchez Pedraza,et al.  Metodología de calificación y resumen de las opiniones dentro de consensos formales , 2009 .

[76]  L. Erickson,et al.  Evidence and Value: Impact on DEcisionMaking – the EVIDEM framework and potential applications , 2008, BMC health services research.

[77]  G. Wilensky Developing A Center For Comparative Effectiveness , 2006 .

[78]  A. Miners,et al.  Economic evaluations of prophylaxis with clotting factor for people with severe haemophilia: why do the results vary so much? , 2013, Haemophilia : the official journal of the World Federation of Hemophilia.

[79]  E. Nord Health Status Index Models for Use in Resource Allocation Decisions: A Critical Review in the Light of Observed Preferences for Social Choice , 1996, International Journal of Technology Assessment in Health Care.

[80]  A. Schutz On Phenomenology And Social Relations , 1970 .

[81]  J. Levy,et al.  AIDS retrovirus antibodies in hemophiliacs treated with factor VIII or factor IX concentrates, cryoprecipitate, or fresh frozen plasma: prevalence, seroconversion rate, and clinical correlations. , 1986, Blood.

[82]  Sean D Sullivan,et al.  Health technology assessment for resource allocation decisions: Are key principles relevant for Latin America? , 2010, International Journal of Technology Assessment in Health Care.

[83]  J. Dolan Multi-Criteria Clinical Decision Support , 2010, The patient.

[84]  E. Santagostino,et al.  Cost–utility analysis of prophylaxis versus treatment on demand in severe hemophilia A , 2011, ClinicoEconomics and outcomes research : CEOR.

[85]  Mark Sculpher,et al.  Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[86]  J. Caro,et al.  Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--7. , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[87]  S. Teutsch,et al.  Episodic versus prophylactic infusions for hemophilia A: a cost-effectiveness analysis. , 1996, The Journal of pediatrics.

[88]  M. Franchini,et al.  The management of hemophilia in elderly patients , 2007, Clinical interventions in aging.

[89]  D. Grobbee,et al.  Variability in clinical phenotype of severe haemophilia: the role of the first joint bleed , 2005, Haemophilia : the official journal of the World Federation of Hemophilia.

[90]  G. Higginbottom Sampling issues in qualitative research. , 2004, Nurse researcher.

[91]  M J Buxton,et al.  Modelling in economic evaluation: an unavoidable fact of life. , 1997, Health economics.

[92]  C. Murray,et al.  Household catastrophic health expenditure: a multicountry analysis , 2003, The Lancet.

[93]  Anthony J Culyer,et al.  National Institute for Clinical Excellence and its value judgments , 2004, BMJ : British Medical Journal.

[94]  C. Sabin,et al.  Cost-Utility Analysis of Primary Prophylaxis versus Treatment On-Demand for Individuals with Severe Haemophilia , 2012, PharmacoEconomics.

[95]  S. Paisley,et al.  Economic modelling of different treatment strategies for haemophilia A with high‐responding inhibitors , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

[96]  H. Leufkens,et al.  Differences in Attitudes, Knowledge and Use of Economic Evaluations in Decision-Making in The Netherlands , 2000, PharmacoEconomics.

[97]  M. Hilgartner Current treatment of hemophilic arthropathy , 2002, Current opinion in pediatrics.

[98]  D. Eddy Evidence-based medicine: a unified approach. , 2005, Health affairs.

[99]  G. Carrasquilla,et al.  Equidad en la Deteccin del Cncer de Seno en Colombia , 2008 .

[100]  C. Ham,et al.  Reasonable Rationing: international experience of priority setting in health care , 2003 .

[101]  P. Petrini Identifying and overcoming barriers to prophylaxis in the management of haemophilia , 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

[102]  K. Fischer,et al.  Prophylaxis for severe haemophilia: clinical and economical issues , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

[103]  M Johannesson,et al.  On the decision rules of cost-effectiveness analysis. , 1993, Journal of health economics.

[104]  W. Gerth,et al.  Use of cost-effectiveness analysis in health-care resource allocation decision-making: how are cost-effectiveness thresholds expected to emerge? , 2004, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[105]  D. Grobbee,et al.  RCTs and observational studies to determine the effect of prophylaxis in severe haemophilia , 2007, Haemophilia : the official journal of the World Federation of Hemophilia.

[106]  A. Gafni,et al.  On being NICE in the UK: guidelines for technology appraisal for the NHS in England and Wales. , 2002, Health economics.

[107]  J. Astermark,et al.  Consensus perspectives on prophylactic therapy for haemophilia: summary statement , 2003, Haemophilia : the official journal of the World Federation of Hemophilia.

[108]  M. Drummond,et al.  Nasty or nice? A perspective on the use of health technology assessment in the United Kingdom. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.

[109]  M. Recht,et al.  Current Options and New Developments in the Treatment of Haemophilia , 2011, Drugs.

[110]  B. Glaser Basics of Grounded Theory Analysis: Emergence Vs. Forcing , 1992 .

[111]  C. Hausl,et al.  Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors , 2007, British journal of haematology.

[112]  L. Prihodova,et al.  A survey of the outcome of prophylaxis, on‐demand or combined treatment in 20–35 year old men with severe haemophilia in four European countries , 2011, Haemophilia : the official journal of the World Federation of Hemophilia.

[113]  Hanane Khoury,et al.  Bridging Health Technology Assessment (HTA) and Efficient Health Care Decision Making with Multicriteria Decision Analysis (MCDA) , 2012, Medical decision making : an international journal of the Society for Medical Decision Making.

[114]  J. Maahs,et al.  Practice patterns in haemophilia A therapy – global progress towards optimal care , 2006, Haemophilia : the official journal of the World Federation of Hemophilia.

[115]  Patrick A Crookes,et al.  Research Into Practice: Essential Skills for Reading and Applying Research in Nursing and Health Care , 1998 .

[116]  J. Mchardy,et al.  Twice weekly prophylactic therapy in haemophilia A. , 1977, Journal of clinical pathology.

[117]  Christine A. Lee,et al.  The best of times, the worst of times , 2001 .

[118]  J. Stockman Prophylaxis versus Episodic Treatment to Prevent Joint Disease in Boys with Severe Hemophilia , 2009 .

[119]  M. Mcgregor,et al.  Assessing the Impact of Health Technology Assessment , 1997, International Journal of Technology Assessment in Health Care.

[120]  E. Murphy,et al.  Qualitative research methods in health technology assessment: a review of the literature. , 1998, Health technology assessment.

[121]  Norbert Schwarz,et al.  Misimagining the unimaginable: the disability paradox and health care decision making. , 2005, Health psychology : official journal of the Division of Health Psychology, American Psychological Association.

[122]  J. Kendall,et al.  Sibling accounts of attention deficit hyperactivity disorder (ADHD). , 1999, Family process.

[123]  P. Mannucci,et al.  Effects of secondary prophylaxis started in adolescent and adult haemophiliacs , 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

[124]  M. Drummond,et al.  IMPLEMENTING THE FINDINGS OF HEALTH TECHNOLOGY ASSESSMENTS , 2000, International Journal of Technology Assessment in Health Care.

[125]  G Loomes,et al.  Visual Analog Scales, Standard Gambles, and Relative Risk Aversion , 2001, Medical decision making : an international journal of the Society for Medical Decision Making.

[126]  R. Baltussen,et al.  Priority setting of health interventions: the need for multi-criteria decision analysis , 2006, Cost effectiveness and resource allocation : C/E.

[127]  Christopher McCabe,et al.  Health Technology Funding Decision-Making Processes Around the World , 2011, PharmacoEconomics.

[128]  Anselm L. Strauss,et al.  Awareness of Dying , 1966 .

[129]  Douglas K. Martin,et al.  Accountable priority setting for trust in health systems - the need for research into a new approach for strengthening sustainable health action in developing countries , 2009, Health research policy and systems.

[130]  L. Valentino,et al.  Prophylaxis for severe haemophilia: clinical challenges in the absence as well as in the presence of inhibitors , 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

[131]  V. Blanchette,et al.  Cost‐utility analysis of Canadian tailored prophylaxis, primary prophylaxis and on‐demand therapy in young children with severe haemophilia A , 2008, Haemophilia : the official journal of the World Federation of Hemophilia.

[132]  D. Feeny,et al.  Multiattribute utility function for a comprehensive health status classification system. Health Utilities Index Mark 2. , 1996, Medical care.

[133]  M. Mcgregor Can our health services be saved by technology evaluation? The Quebec experience. , 1994, Clinical and investigative medicine. Medecine clinique et experimentale.

[134]  F. Mandelli,et al.  Evaluation of prophylactic replacement therapy in haemophilia B. , 2009, Scandinavian journal of haematology.

[135]  J. Oldenburg,et al.  Haemophilia care then, now and in the future , 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

[136]  M. Hammersley What's Wrong With Ethnography? , 1991 .

[137]  P. Taylor Clinical Decision Making: From Theory to Practice , 1996 .

[138]  J. Ingerslev,et al.  Utility of the Haemophilia Joint Health Score in study of episodically treated boys with severe haemophilia A and B in Lithuania , 2010, Haemophilia : the official journal of the World Federation of Hemophilia.

[139]  M. Johannesson The Australian Guidelines for Subsidisation of Pharmaceuticals , 1992, PharmacoEconomics.

[140]  R. Engelbert,et al.  Validation of a new pediatric joint scoring system from the International Hemophilia Prophylaxis Study Group: Validity of the hemophilia joint health score , 2011, Arthritis care & research.

[141]  Lisa A Bero,et al.  "Developing good taste in evidence": facilitators of and hindrances to evidence-informed health policymaking in state government. , 2008, The Milbank quarterly.

[142]  D. Czepa,et al.  Cross sectional study to investigate the influence of treatment regimes on the development of haemophilic arthropathy. , 2009, Hamostaseologie.

[143]  M. Rawlins In pursuit of quality: the National Institute for Clinical Excellence , 1999, The Lancet.

[144]  J. Mamikhani,et al.  Cost-effectiveness of prophylaxis against on-demand treatment in boys with severe hemophilia A in Iran , 2009, International Journal of Technology Assessment in Health Care.

[145]  Scharrer,et al.  Incidence of inhibitors in haemophilia A patients – a review of recent studies of recombinant and plasma‐derived factor VIII concentrates , 1999, Haemophilia : the official journal of the World Federation of Hemophilia.

[146]  M. Drummond,et al.  Economic Evaluation in Health Care: Merging Theory with Practice , 2002 .

[147]  H. Pettersson,et al.  Twenty‐five years' experience of prophylactic treatment in severe haemophilia A and B , 1992, Journal of internal medicine.

[148]  E. Berntorp Joint outcomes in patients with haemophilia: the importance of adherence to preventive regimens , 2009, Haemophilia : the official journal of the World Federation of Hemophilia.

[149]  P. Rosenau Managing Medical Technology: Lessons for the United States from Quebec and France , 2000, International journal of health services : planning, administration, evaluation.

[150]  V. Braun,et al.  Using thematic analysis in psychology , 2006 .

[151]  Frank A. Sloan,et al.  Valuing health care : costs, benefits, and effectiveness of pharmaceuticals and other medical technologies , 1995 .

[152]  C. Casas,et al.  The History and Evolution of the Clinical Effectiveness of Haemophilia Type A Treatment: A Systematic Review , 2014, Indian Journal of Hematology and Blood Transfusion.

[153]  V. Jiménez‐Yuste,et al.  Is on‐demand treatment effective in patients with severe haemophilia? , 2012, Haemophilia : the official journal of the World Federation of Hemophilia.

[154]  A. Coppola,et al.  Primary prophylaxis in children with haemophilia. , 2008, Blood transfusion = Trasfusione del sangue.

[155]  J. Aznar,et al.  The orthopaedic status of severe haemophiliacs in Spain , 2000, Haemophilia : the official journal of the World Federation of Hemophilia.